Anticonvulsants for alcohol withdrawal

Risk Locus Identification Ties Alcohol Withdrawal Symptoms toSORCS2

“…Recruitment of new and larger samples will be needed for confirmation and further characterization of SNP effects across different clinical settings. The results from our GWAS and the SANAD trial are consistent with the expectation that overlapping biological pathways would be relevant to illnesses with overlapping pharmacotherapies (Henriksen, 1998; Minozzi et al, 2010; VonDran et al, 2014). As is often the case in complex trait genetics, we observed population-specific associations with common variants (CONVERGE consortium, 2015).…”

Risk Locus Identification Ties Alcohol Withdrawal Symptoms toSORCS2

“…Recruitment of new and larger samples will be needed for confirmation and further characterization of SNP effects across different clinical settings. The results from our GWAS and the SANAD trial are consistent with the expectation that overlapping biological pathways would be relevant to illnesses with overlapping pharmacotherapies (Henriksen, 1998; Minozzi et al, 2010; VonDran et al, 2014). As is often the case in complex trait genetics, we observed population-specific associations with common variants (CONVERGE consortium, 2015).…”

The effectiveness and tolerability of anti‐seizure medication in alcohol withdrawal syndrome: a systematic review, meta‐analysis and GRADE of the evidence

“…Differences exist in our study compared to previous meta-analyses [7], although three trials [16][17][18] on carbamazepine were shown to potentially demonstrate efficacy in reducing overall CIWA-Ar scores in the meta-analysis by Minozzi et al it should be noted that our chosen CIWA-Ar score outcome timepoint (up to 4 days) differs from the Minozzi review (48 hours), because this was thought to be more clinically relevant, because the majority of AWS symptoms peak within the first 4 days. Additionally, all studies used high carbamazepine dosing (600-800 mg per day), significantly higher than the BNF suggested initiation dose of 100 mg/day.…”

“…There were substantially high dropout rates in most RCTs, leading to high risk of bias judgments regarding attrition bias. This is another major difference from previous studies [7], because no previous reviews have used GRADE methodology, we can report that any newly conducted trials are likely to affect almost all estimates.…”

Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis

“…The glutamatergic agents lamotrigine, memantine, and topiramate have preliminary efficacy in AW [27,34]. However, we did not find evidence favoring these agents in the present NMA.…”

Risk Locus Identification Ties Alcohol Withdrawal Symptoms toSORCS2

“…Recruitment of new and larger samples will be needed for confirmation and further characterization of SNP effects across different clinical settings. The results from our GWAS and the SANAD trial are consistent with the expectation that overlapping biological pathways would be relevant to illnesses with overlapping pharmacotherapies (Henriksen, 1998; Minozzi et al, 2010; VonDran et al, 2014). As is often the case in complex trait genetics, we observed population-specific associations with common variants (CONVERGE consortium, 2015).…”

The effectiveness and tolerability of anti‐seizure medication in alcohol withdrawal syndrome: a systematic review, meta‐analysis and GRADE of the evidence

“…Differences exist in our study compared to previous meta-analyses [7], although three trials [16][17][18] on carbamazepine were shown to potentially demonstrate efficacy in reducing overall CIWA-Ar scores in the meta-analysis by Minozzi et al it should be noted that our chosen CIWA-Ar score outcome timepoint (up to 4 days) differs from the Minozzi review (48 hours), because this was thought to be more clinically relevant, because the majority of AWS symptoms peak within the first 4 days. Additionally, all studies used high carbamazepine dosing (600-800 mg per day), significantly higher than the BNF suggested initiation dose of 100 mg/day.…”

“…There were substantially high dropout rates in most RCTs, leading to high risk of bias judgments regarding attrition bias. This is another major difference from previous studies [7], because no previous reviews have used GRADE methodology, we can report that any newly conducted trials are likely to affect almost all estimates.…”

Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis

“…The glutamatergic agents lamotrigine, memantine, and topiramate have preliminary efficacy in AW [27,34]. However, we did not find evidence favoring these agents in the present NMA.…”

Risk Locus Identification Ties Alcohol Withdrawal Symptoms toSORCS2

“…Recruitment of new and larger samples will be needed for confirmation and further characterization of SNP effects across different clinical settings. The results from our GWAS and the SANAD trial are consistent with the expectation that overlapping biological pathways would be relevant to illnesses with overlapping pharmacotherapies (Henriksen, 1998; Minozzi et al, 2010; VonDran et al, 2014). As is often the case in complex trait genetics, we observed population-specific associations with common variants (CONVERGE consortium, 2015).…”

The effectiveness and tolerability of anti‐seizure medication in alcohol withdrawal syndrome: a systematic review, meta‐analysis and GRADE of the evidence

“…Differences exist in our study compared to previous meta-analyses [7], although three trials [16][17][18] on carbamazepine were shown to potentially demonstrate efficacy in reducing overall CIWA-Ar scores in the meta-analysis by Minozzi et al it should be noted that our chosen CIWA-Ar score outcome timepoint (up to 4 days) differs from the Minozzi review (48 hours), because this was thought to be more clinically relevant, because the majority of AWS symptoms peak within the first 4 days. Additionally, all studies used high carbamazepine dosing (600-800 mg per day), significantly higher than the BNF suggested initiation dose of 100 mg/day.…”

“…There were substantially high dropout rates in most RCTs, leading to high risk of bias judgments regarding attrition bias. This is another major difference from previous studies [7], because no previous reviews have used GRADE methodology, we can report that any newly conducted trials are likely to affect almost all estimates.…”

Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis

“…The glutamatergic agents lamotrigine, memantine, and topiramate have preliminary efficacy in AW [27,34]. However, we did not find evidence favoring these agents in the present NMA.…”